Larimar Therapeutics, Inc. (LRMR) Misses Q3 EPS by 20c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q3 EPS of ($0.61), $0.20 worse than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• FDA approves Takeda's rusfertide for polycythemia vera treatment
• Honda and Nissan to jointly develop vehicle sofware, Nikkei reports